합성 카나비노이드 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Synthetic Cannabinoids Market size is expected to reach USD 33.63 Billion in 2034 from USD 5.88 Billion (2025) growing at a CAGR of 21.39% during 2026-2034.

The synthetic cannabinoids market is growing steadily, fueled by ongoing research into novel therapeutic applications and evolving regulatory landscapes. Unlike natural cannabinoids, synthetic variants are engineered to interact with cannabinoid receptors in precise ways, offering potential for treatments in pain management, neurodegenerative disorders, and oncology. However, the market is also shaped by strict compliance requirements due to concerns over misuse, toxicity, and unregulated distribution.

Pharmaceutical companies and research institutions are focusing on developing safe, standardized synthetic cannabinoid formulations. Advances in molecular modeling and biotechnology are enabling the design of compounds with targeted therapeutic effects while minimizing adverse reactions. Clinical trials and patent filings are increasing, indicating strong momentum toward commercialized cannabinoid-based medicines. Meanwhile, the adoption of stringent quality control standards is ensuring consistency and safety in production.

Looking forward, the market will benefit from increasing acceptance of cannabinoid therapies and progressive regulatory frameworks in developed regions. Opportunities will also emerge in synthetic alternatives to cannabis-derived products, offering consistent dosing and scalability. As personalized medicine and precision therapeutics gain prominence, synthetic cannabinoids are likely to find wider application across healthcare. Strategic partnerships between biotech innovators and pharmaceutical giants will accelerate market maturity.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• High-pure Synthetic Cannabinoid
• Ultra-pure Synthetic Cannabinoid

By Indication

• Pain Management
• Nausea/Vomiting
• Neurological Disorder Management
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Mylan NV, Alkem Labs, Noramco, Lygos Inc, Hyasynth Biologicals Inc, Renew Biopharma, CannBioRx Life Sciences, Ginkgo Bioworks, Zymergen Inc, Demetrix Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. High-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ultra-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Nausea/Vomiting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neurological Disorder Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SYNTHETIC CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V
  • 9.2.2 Alkem Labs
  • 9.2.3 Noramco
  • 9.2.4 Lygos Inc
  • 9.2.5 Hyasynth Biologicals Inc
  • 9.2.6 Renew Biopharma
  • 9.2.7 CannBioRx Life Sciences
  • 9.2.8 Ginkgo Bioworks
  • 9.2.9 Zymergen Inc
  • 9.2.10 Demetrix Inc